Related references
Note: Only part of the references are listed.Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244
Peter J. Hoskin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support
Jyoti Nangalia et al.
LEUKEMIA & LYMPHOMA (2008)
New aspects in descriptive, etiologic, and molecular epidemiology of Hodgkin's lymphoma
Ola Landgren et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2007)
Meta-analysis: Effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection
Lillian Sung et al.
ANNALS OF INTERNAL MEDICINE (2007)
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis
Andrew M. Evens et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors
E. Boleti et al.
ANNALS OF ONCOLOGY (2007)
Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma
Anas Younes et al.
EUROPEAN JOURNAL OF CANCER (2006)
2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline
Thomas J. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients
NM Kuderer et al.
CANCER (2006)
Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma
WG Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy
V Caggiano et al.
CANCER (2005)
Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease
DJ Straus et al.
BLOOD (2004)
Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy:: results after 7 years of a prospective study
AR Domínguez et al.
ANNALS OF ONCOLOGY (2004)
Effects of granulocyte colony-stimulating factor (G-CSF) on bleomycin-induced lung injury of varying severity
K Adachi et al.
TOXICOLOGIC PATHOLOGY (2003)
Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis
E Azoulay et al.
CRITICAL CARE MEDICINE (2003)
Secondary prophylactic C-CSF (filgrastim) administration in chemotherapy of stage I and II Hodgkin's lymphoma with ABVD
A Rueda et al.
LEUKEMIA & LYMPHOMA (2001)